Published: 10th March 2022 - All information correct at time of publication.
Leading pathology provider SYNLAB UK & Ireland is looking forward to welcoming biomedical scientists to its stand at the IBMS Congress 2022 next week.
Representatives from SYNLAB – Europe’s leading medical diagnostics expert – will be on hand to talk to attendees about the variety of career opportunities on offer across its four NHS pathology partnerships and other businesses during the conference, from 14 to 17 March at Birmingham’s International Convention Centre (ICC).
SYNLAB is dedicated to improving patient care through its NHS pathology partnerships and has a track record of implementing ‘hub and spoke’ pathology models, building state-of-the-art laboratories to offer faster, more consistent and higher-quality testing services which help speed up diagnosis and clinical decision making.
The newest of its NHS pathology partnerships is with Viapath in South East London with Guy’s and St Thomas’, and King’s College Hospital NHS Foundation Trusts. The partnership came into being just a year ago, in line with the NHS’s clinical vision, and is the fourth of SYNLAB’s partnerships alongside Southwest Pathology Services in Somerset, Pathology First in Essex and The Christie Pathology Partnership in Manchester.
This year’s IBMS Congress will provide an opportunity for SYNLAB to talk about its work and activities across the NHS, and its commitment to improving laboratory, scientific and clinical practice through transformation, investment and innovation.
The SYNLAB-NHS partnership aims to drive innovation across the pathology field – we want to lead the way in scientific and technological development for the benefit of our patients.
We’re really looking forward to the IBMS Congress 2022, and in particular having the chance to demonstrate everything that’s great about a career with SYNLAB to those who share our values and might be interested in joining us
Dominic Harrington, Viapath Chief Scientific Officer
With access to world-leading expertise – alongside learning and development opportunities across its diverse businesses – SYNLAB expects to perform more than 50 million tests across its UK & Ireland businesses in 2022, offering rewarding careers for scientists, and others, who want to make a positive difference to people, animals and the environment.
In addition to its NHS pathology partnerships, the business portfolio also includes SYNLAB Laboratory Services, Lextox and SYNLAB Veterinary Group.
Our people are our biggest asset at SYNLAB, and this is why being part of the IBMS Congress 2022 is so important to us. We are committed to driving improvement and making a positive difference to those who use our services through science and innovation, bringing new talent to our businesses and investing in our existing workforce.
We can’t wait to talk to aspiring and established scientists about our fantastic work across all our businesses, including through our NHS partnerships, and look forward to being part of the IBMS Congress.
Mark Dollar, SYNLAB UK & Ireland Chief Executive
SYNLAB will be on stand 915 at the IBMS Congress, where current employees from across its businesses will be able to provide insights and information about pathways into pathology and biomedical science careers. Visitors to the stand will also be able to enter a competition to win prizes that include an iPad.
Our current opportunities are shown on our careers page of our website.
More information about IBMS Congress 2022 can be found at https://congress.ibms.org
